-
1.发明申请METHOD FOR SCREENING OF SUBSTANCE EFFECTIVE ON DISEASE USING GPR120 AND PHOSPHOLIPASE 失效使用GPR120和磷脂酶筛选有害疾病的方法公开(公告)号：US20110183318A1
公开(公告)日：2011-07-28
申请号：US11991441
申请日：2006-09-01
CPC分类号： G01N33/566 , G01N2333/595 , G01N2333/918
摘要： The present invention provides a screening method for determining whether a substance of interest is a substance which alters GPR120 mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR120, or cells containing said biomembrane, and phospholipase or salts thereof. According to a screening method of the present invention, the method can screen substances such as CCK and GLP-1 which are involved in the secretion of hormones in gastrointestinal tracts.
摘要翻译： 本发明提供一种筛选方法，用于确定感兴趣的物质是否是改变GPR120介导的细胞刺激活性的物质，包括使用感兴趣的物质，含有GPR120的生物膜或含有所述生物膜的细胞，以及磷脂酶或其盐。 根据本发明的筛选方法，该方法可以筛选参与胃肠道中激素分泌的诸如CCK和GLP-1的物质。
-
2.发明申请Method of Screening Substance Useful in Treating Disease With the Use of GPR40 and Phospholipase 失效使用GPR40和磷脂酶筛选可用于治疗疾病的物质的方法公开(公告)号：US20100227350A1
公开(公告)日：2010-09-09
申请号：US12084697
申请日：2006-10-17
CPC分类号： G01N33/74 , C12Q1/34 , G01N2333/918 , G01N2500/00
摘要： The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.
摘要翻译： 本发明涉及一种用于确定感兴趣物质是否是改变GPR40介导的细胞刺激活性的物质的筛选方法，其包括使用感兴趣的物质，含有GPR40的生物膜或含有所述生物膜的细胞，以及磷脂酶或其盐 。 根据本发明，可以筛选参与胰岛素分泌的物质。 此外，根据本发明，可用于预防或治疗糖尿病，糖尿病并发症和退行性疾病，高血糖症，多尿症，酮血症，酸中毒，胰岛素抵抗，葡萄糖耐量降低，神经变性疾病，胰岛素瘤，癌症，高胰岛素血症，高甘油三酯血症 ，脂肪肝，胰岛素分泌过多引起的低血糖，动脉硬化，高脂血症，脑中风，肥胖，糖尿病或肥胖引起的各种疾病等。
-
3.发明授权Method for screening of substance which alter GPR120-mediated cell-stimulating activities 失效筛选改变GPR120介导的细胞刺激活性的物质的方法公开(公告)号：US08399204B2
公开(公告)日：2013-03-19
申请号：US11991441
申请日：2006-09-01
IPC分类号： G01N33/53 , G01N33/567
CPC分类号： G01N33/566 , G01N2333/595 , G01N2333/918
摘要： The present invention provides a screening method for determining whether a substance of interest is a substance which alters GPR120 mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR120, or cells containing said biomembrane, and phospholipase or salts thereof. According to a screening method of the present invention, the method can screen substances such as CCK and GLP-1 which are involved in the secretion of hormones in gastrointestinal tracts.
摘要翻译： 本发明提供一种筛选方法，用于确定感兴趣的物质是否是改变GPR120介导的细胞刺激活性的物质，包括使用感兴趣的物质，含有GPR120的生物膜或含有所述生物膜的细胞，以及磷脂酶或其盐。 根据本发明的筛选方法，该方法可以筛选参与胃肠道中激素分泌的诸如CCK和GLP-1的物质。
-
4.发明授权Method of screening substance useful in treating disease with the use of GPR40 and phospholipase 失效使用GPR40和磷脂酶处理疾病的筛选物质的方法公开(公告)号：US08252521B2
公开(公告)日：2012-08-28
申请号：US12084697
申请日：2006-10-17
CPC分类号： G01N33/74 , C12Q1/34 , G01N2333/918 , G01N2500/00
摘要： The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.
摘要翻译： 本发明涉及一种用于确定感兴趣物质是否是改变GPR40介导的细胞刺激活性的物质的筛选方法，其包括使用感兴趣的物质，含有GPR40的生物膜或含有所述生物膜的细胞，以及磷脂酶或其盐 。 根据本发明，可以筛选参与胰岛素分泌的物质。 此外，根据本发明，可用于预防或治疗糖尿病，糖尿病并发症和退行性疾病，高血糖症，多尿症，酮血症，酸中毒，胰岛素抵抗，葡萄糖耐量降低，神经变性疾病，胰岛素瘤，癌症，高胰岛素血症，高甘油三酯血症 ，脂肪肝，胰岛素分泌过多引起的低血糖，动脉硬化，高脂血症，脑中风，肥胖，糖尿病或肥胖引起的各种疾病等。
-
5.发明授权Methods of affecting feeding and weight in mammals by administration of relaxin-3 失效通过施用松弛素-3影响哺乳动物饲喂和体重的方法公开(公告)号：US07638490B2
公开(公告)日：2009-12-29
申请号：US10588542
申请日：2005-02-09
申请人： Takayuki Hida , Tomoko Sekiya , Toru Sawai , Takashi Seiki , Eiki Takahashi , Michiko Kosasa , Kokichi Harada , Tohru Arai
发明人： Takayuki Hida , Tomoko Sekiya , Toru Sawai , Takashi Seiki , Eiki Takahashi , Michiko Kosasa , Kokichi Harada , Tohru Arai
CPC分类号： A61K38/17 , G01N33/566 , G01N2500/04 , Y02A50/406
摘要： Relaxin-3 is found to have feeding-stimulating activity, body weight increasing activity, and fat weight increasing activity when intracerebroventricularly administered to rats through observation of amount of feeding, body weight and fat weight after administration of relaxin-3. This invention includes: a polypeptide having useful effects in stimulating feeding, increasing body weight, and fattening; a therapeutic agent containing the polypeptide; a method of screening for a compound, a substance, or a salt thereof which activates or suppresses a receptor of the polypeptide; a kit for screening; and an agent with a substance which inhibits expression of the polypeptide, such as a feeding-suppressing agent, a therapeutic agent for the treatment of obesity, and a therapeutic agent for the treatment of diabetes.
摘要翻译： 发现松弛素-3在给予松弛素-3后，通过观察饲喂量，体重和脂肪重量，通过大鼠脑室内施用，具有摄食刺激活性，体重增加活性和脂肪增加活性。 本发明包括：具有刺激喂养，增加体重和育肥的有效作用的多肽; 含有该多肽的治疗剂; 筛选活化或抑制多肽受体的化合物，物质或其盐的方法; 一套筛选工具; 以及具有抑制多肽表达的物质，例如进食抑制剂，治疗肥胖症的治疗剂和用于治疗糖尿病的治疗剂的药剂。
-
公开(公告)号：US20070054850A1
公开(公告)日：2007-03-08
申请号：US10588542
申请日：2005-02-09
申请人： Takayuki Hida , Tomoko Sekiya , Toru Sawai , Takashi Seiki , Eiki Takahashi , Michiko Kosasa , Kokichi Harada , Tohru Arai
发明人： Takayuki Hida , Tomoko Sekiya , Toru Sawai , Takashi Seiki , Eiki Takahashi , Michiko Kosasa , Kokichi Harada , Tohru Arai
CPC分类号： A61K38/17 , G01N33/566 , G01N2500/04 , Y02A50/406
摘要： The present inventors have found that relaxin-3 has a feeding-stimulating activity, a body weight increasing activity, and fat weight increasing activity by intracerebroventricularly administering relaxin-3 to rats and observing the amount of feeding, body weight and fat weight, and so on after the administration. According to the present invention, a polypeptide having useful effects in stimulating feeding, increasing body weight, and fattening; a therapeutic agent containing said polypeptide; a method of screening for a compound, a substance, or a salt thereof which activates or suppresses a receptor of said polypeptide; a kit for said screening; and an agent which comprises a substance which inhibits expression of said polypeptide, such as a feeding-surpressing agent, a therapeutic agent for the treatment of obesity, and a therapeutic agent for the treatment of diabetes.
摘要翻译： 本发明人已经发现松弛素-3具有喂养刺激活性，体重增加活性和通过脑内给予松弛素-3对大鼠的体重增加活性，观察喂养量，体重和脂肪重量等 在管理之后。 根据本发明，具有刺激进食，增加体重和育肥的有效作用的多肽; 含有所述多肽的治疗剂; 筛选活化或抑制所述多肽受体的化合物，物质或其盐的方法; 用于筛选的试剂盒; 以及包含抑制所述多肽表达的物质的试剂，例如饲料抑制剂，治疗肥胖症的治疗剂和治疗糖尿病的治疗剂。
-
公开(公告)号：US20100168014A1
公开(公告)日：2010-07-01
申请号：US12591105
申请日：2009-11-09
申请人： Takayuki Hida , Tomoko Sekiya , Toru Sawai , Takashi Seiki , Eiki Takahashi , Michiko Kosasa , Kokichi Harada , Toru Arai
发明人： Takayuki Hida , Tomoko Sekiya , Toru Sawai , Takashi Seiki , Eiki Takahashi , Michiko Kosasa , Kokichi Harada , Toru Arai
CPC分类号： A61K38/17 , G01N33/566 , G01N2500/04 , Y02A50/406
摘要： The present inventors have found that relaxin-3 has a feeding-stimulating activity, a body weight increasing activity, and fat weight increasing activity by intracerebroventricularly administering relaxin-3 to rats and observing the amount of feeding, body weight and fat weight, and so on after the administration. According to the present invention, a polypeptide having useful effects in stimulating feeding, increasing body weight, and fattening; a therapeutic agent containing said polypeptide; a method of screening for a compound, a substance, or a salt thereof which activates or suppresses a receptor of said polypeptide; a kit for said screening; and an agent which comprises a substance which inhibits expression of said polypeptide, such as a feeding-surpressing agent, a therapeutic agent for the treatment of obesity, and a therapeutic agent for the treatment of diabetes.
摘要翻译： 本发明人已经发现松弛素-3具有喂养刺激活性，体重增加活性和通过脑内给予松弛素-3对大鼠的体重增加活性，观察喂养量，体重和脂肪重量等 在管理之后。 根据本发明，具有刺激进食，增加体重和育肥的有效作用的多肽; 含有所述多肽的治疗剂; 筛选活化或抑制所述多肽受体的化合物，物质或其盐的方法; 用于筛选的试剂盒; 以及包含抑制所述多肽表达的物质的试剂，例如饲料抑制剂，治疗肥胖症的治疗剂和治疗糖尿病的治疗剂。
-
公开(公告)号：US20090311185A1
公开(公告)日：2009-12-17
申请号：US11919145
申请日：2006-04-26
申请人： Takayuki Hida , Toru Arai , Tomoko Sekiya , Eiki Takahashi , Kodo Shikata
发明人： Takayuki Hida , Toru Arai , Tomoko Sekiya , Eiki Takahashi , Kodo Shikata
CPC分类号： G01N33/6896 , A61K38/2221 , C07K14/64 , G01N2500/04 , G01N2800/301
摘要： The objects of the present invention are to provide a polypeptide having an antianxiety activity; a therapeutic agent containing the polypeptide; a method for treating anxiety using the polypeptide; a method of screening for a compound capable of activating or suppressing a receptor for the polypeptide and involved in the regulation of anxiety, a salt thereof, or a hydrate of them; and a kit for the screening. There is provided an antianxiety agent containing relaxin-3.
摘要翻译： 本发明的目的是提供具有抗焦虑活性的多肽; 含有该多肽的治疗剂; 使用该多肽治疗焦虑症的方法; 筛选能够激活或抑制多肽受体并参与焦虑调节的化合物，其盐或其水合物的方法; 和一个试剂盒进行筛选。 提供含有松弛素-3的抗焦虑剂。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.025 秒)